References
- Wahl P, Walden C, Knopp R, et al. Effect of estrogen/ progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983; 308: 862–67
- Bradley D D., Wingerd J, Pettiti D B., Krauss R M., Ramcharan S. Serum high-density lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med 1978; 299: 17–20
- Gordon T, Castelli W P., Hjortland M C., et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977; 62: 707–14
- Miller G J. High density lipoproteins and atherosclerosis. Ann Rev Med 1980; 31: 97–108
- Phillips A. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990; 41(4)399–410
- Chapdelaine A, Desmarais J L., Derman R J. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989; 34: 347–52
- Corson S L. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials. Acta Obstet Gynecol Scand Suppl 1990; 69: 25–31
- Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1990; 69: 33–39
- Friedewald W T., Levi R I., Fredrickson D S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultra centrifuge. Clin Chem 1972; 18: 499–502
- Patsch W, Brown S A., Gotto A M., Jr, Young R L. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. Am J Obstet Gynecol 1989; 161: 1396–401
- Fotherby K. Update on lipid metabolism and oral contraception. Br J Fam Plann 1990; 15: 33–6, (suppl)